TY - JOUR
T1 - Targeting epidermal growth factor receptor in tumors
T2 - From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies
AU - Altintas, I.
AU - Kok, R.J.
AU - Schiffelers, R.M.
PY - 2012/3/12
Y1 - 2012/3/12
N2 - The discovery of naturally occurring heavy chain only antibodies and their further development into small recombinant 'nanobodies' offers attractive applications in drug targeting. Here, we describe the properties of nanobodies that have been developed to target the epidermal growth factor receptor (EGFR) and contrast these to the characteristics of heavy chain only antibodies and conventional antibodies. EGFR is overexpressed in many tumors and is an attractive target for tumor-directed drug targeting.
AB - The discovery of naturally occurring heavy chain only antibodies and their further development into small recombinant 'nanobodies' offers attractive applications in drug targeting. Here, we describe the properties of nanobodies that have been developed to target the epidermal growth factor receptor (EGFR) and contrast these to the characteristics of heavy chain only antibodies and conventional antibodies. EGFR is overexpressed in many tumors and is an attractive target for tumor-directed drug targeting.
KW - Antibody
KW - Drug delivery systems
KW - Epidermal growth factor receptor
KW - Nanobody
UR - http://www.scopus.com/inward/record.url?scp=84856282034&partnerID=8YFLogxK
U2 - 10.1016/j.ejps.2011.10.015
DO - 10.1016/j.ejps.2011.10.015
M3 - Article
C2 - 22064454
SN - 0928-0987
VL - 45
SP - 399
EP - 407
JO - European Journal of Pharmaceutical Sciences
JF - European Journal of Pharmaceutical Sciences
IS - 4
ER -